Skip to main content
    Q

    Quince Therapeutics, Inc. (QNCX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $31.73
    +0.00 (+0.00%)

    Market Cap: $32.27M

    Last updated: Oct 13, 2026 at 5:00 PM ET

    Quince Therapeutics, Inc. (QNCX) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Quince Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$83.98M, operating cash flow was -$41.42M and free cash flow was -$41.78M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$27.74M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $58.07M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Cost of revenue$0$0$0$0$0$0$0$0$45.00K
    Gross profit$0$0$0$0$0$0$0$0-$45.00K
    Research and development$35.38M$18.59M$9.45M$25.18M$60.80M$61.31M$30.21M$10.09M$9.10M
    Operating income-$58.07M-$57.28M-$34.62M-$52.02M-$90.32M-$78.89M-$39.17M-$12.12M-$10.37M
    Net income-$83.98M-$56.83M-$31.39M-$51.66M-$89.94M-$76.85M-$36.98M-$12.48M-$12.23M
    EBITDAN/AN/AN/AN/A-$89.34M-$77.93MN/AN/A-$10.32M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$168.00K$0$0$0$0
    Gross profit$0$0$0N/A$0$0$0-$16.00K$0$0$0N/A
    Operating income-$13.14M-$79.78M-$14.59M-$19.35M-$13.43M-$10.43M-$14.86M-$12.01M-$5.86M-$28.19M-$11.22M-$9.99M
    Net income-$27.74M-$75.49M$35.91M-$39.46M-$13.44M-$16.05M-$15.03M-$12.46M-$5.49M-$27.73M-$11.15M-$8.89M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $30.39M exceeded cash and equivalents by $24.59M. Shareholder equity was negative, at -$35.71M, as total liabilities of $129.24M exceeded total assets of $93.52M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$93.52M$114.48M$167.90M$103.91M$133.23M$189.47M$124.37M$72.88M$7.72M
    Current assets$22.90M$44.04M$77.44M$93.75M$111.67M$137.86M$106.06M$72.58M$7.54M
    Cash and equivalents$5.81M$6.21M$20.75M$44.58M$69.72M$66.84M$51.21M$24.87M$7.34M
    Total liabilities$129.24M$84.33M$82.82M$3.32M$14.64M$17.20M$8.89M$1.46M$28.00M
    Short-term debt$30.39M$0$4.10M$0$741.00K$238.00KN/AN/AN/A
    Long-term debtN/A$14.32M$13.43M$0N/AN/AN/AN/AN/A
    Shareholder equity-$35.71M$30.15M$85.08M$100.59M$118.59M$172.26M$115.48M-$32.63M-$20.28M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$106.47M$124.00M$26.62M$93.52M$109.90M$117.21M$107.09M$114.48M$126.52M$134.83M$159.29M$167.90M
    Total liabilities$28.37M$15.51M$10.95M$129.24M$108.84M$105.47M$88.51M$84.33M$81.59M$87.86M$85.11M$82.82M
    Cash and equivalents$39.82M$115.98M$18.16M$5.81M$6.45M$16.83M$7.77M$6.21M$2.67M$7.89M$21.81M$20.75M
    Shareholder equity-$65.70M-$35.32M$15.67M-$35.71M$1.06M$11.74M$18.58M$30.15M$44.93M$46.97M$74.18M$85.08M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$41.42M-$31.90M-$18.29M-$44.04M-$62.93M-$50.82M-$33.28M-$11.70M-$9.83M
    Capital expenditures$352.00K$257.00K$160.00K$133.00K$180.00K$52.00K$55.00K$212.00K$77.00K
    Free cash flow-$41.78M-$32.16M-$18.45M-$44.17M-$63.11M-$50.87M-$33.33M-$11.91M-$9.90M
    Investing cash flow$23.23M$21.91M-$5.76M$18.00M$58.95M-$52.43M-$17.75M-$46.75M-$77.00K
    Financing cash flow$17.91M-$4.78M$143.00K$707.00K$6.81M$118.88M$77.37M$75.93M$7.75M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$9.84M-$18.89M-$7.63M-$10.48M-$9.93M-$11.41M-$9.60M-$7.55M-$7.26M-$8.74M-$8.35M-$6.08M
    Capital expenditures$71.00KN/A$0$4.00K$74.00K$126.00K$148.00K$133.00K$46.00K$39.00K$39.00K$24.00K
    Free cash flow-$9.91MN/A-$7.63M-$10.48M-$10.00M-$11.54M-$9.75M-$7.68M-$7.31M-$8.78M-$8.39M-$6.10M
    Last 12 quarters

    Frequently Asked Questions About QNCX

    What is Quince Therapeutics' annual revenue?

    Quince Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Quince Therapeutics profitable?

    No. Quince Therapeutics reported net income of -$83.98M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does QNCX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$41.42M minus capital expenditures of $352.00K produced free cash flow of -$41.78M.

    How much debt does Quince Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $30.39M and cash and equivalents of $5.81M.